osteoclast precursor cells

VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).

Y1693 is an orally active RANKL inhibitor with a Kd value of 5.03 μM for hRANKL. Y1693 inhibits activation of the downstream c-fos/NFATc1 signaling pathway by blocking the interaction between RANKL and RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation, and bone resorptive activity while downregulating the mRNA and protein expression levels of TRAP, cathepsin K, c-fos, and NFATc1. Y1693 demonstrates no obvious cytotoxicity toward bone marrow-derived macrophages and osteoclast precursor cells and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research involving osteoporosis, osteoclast biology, and periodontal disease-associated bone remodeling mechanisms.